Eisai Rufinamide Study Reports 33 Percent Reduction In Epileptic Seizures
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug is "approvable" for Lennox-Gastaut syndrome, partial onset seizures since 2006.
You may also be interested in...
FDA Opts For MedGuide, Not Black Box For Anti-Epileptic Suicidality
FDA has made a decision on how to communicate the suicidality risk for anti-epileptic drugs: with the first novel approvals in that class since an advisory committee on the topic, FDA has opted for a Medication Guide over a "black box" warning
FDA Opts For MedGuide, Not Black Box For Anti-Epileptic Suicidality
FDA has made a decision on how to communicate the suicidality risk for anti-epileptic drugs: with the first novel approvals in that class since an advisory committee on the topic, FDA has opted for a Medication Guide over a "black box" warning
Synosia Will Initiate Phase II Studies Of Rufinamide In Anxiety, Bipolar Disorders In March
Company will evaluate 500 mg and 1 gm doses of the drug, after assessing three different doses in a proof-of-concept study.